(AACE 2023 Obesity Guidelines, endocrine.org) The Obesity Society's position statement notes: "Pharmacotherapy for obesity should be considered an adjunct to, not a replacement for, behavioral intervention, and should be maintained long-term in patients who respond." This language directly supports Michigan Medicaid PA criteria requiring concurrent behavioral program participation
Complications from these implants can result in severe pain, the need for revision surgeries, and long-term health impacts
Somatostatin: An inhibitory hormone that suppresses GH release, providing negative feedback to prevent excessive secretion
MayJune 2023
Appetite regulation, involving multiple neural nuclei in the central nervous system, is crucial for obesity treatment [10]
4 The medications appear to be working directly on the inflammatory pathways themselves